Home › Research › Brain tissue and pathology
Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity
Chenyin Chu, Yihan Wang, Liwei Ma, Chloe A. Mutimer, Guangyan Ji, Huiyu Shi, Nawaf Yassi, Colin Louis Masters et al.. Alzheimer s & Dementia, 2025-03-01
Topic: Amyloid, tau and blood-test diagnosis
The FCAAS-4 achieved a mean area under the receiver operating characteristic curve (AUC-ROC) of 0.74 (95% confidence interval: 0.71-0.77) and a Harrell generalized c-index of 0.72 (0.70-0.75). Pilot trial results obtained a mean AUC-ROC of 0.82 (0.71-0.85) and Harrell generalized c-index 0.79 (0.73-0.82). The FCAAS models demonstrate a promising performance in predicting CAA severity. This framework holds the potential for predicting development of amyloid-related imaging abnormalities (ARIAs), given the CAA-ARIAs link. HIGHLIGHTS: The severity of cerebral amyloid angiopathy (CAA) can only be determined post mortem. A web tool, the Florey CAA Score (FCAAS), was developed to predict CAA severity. The FCAAS holds the potential to be used for CAA risk stratification in clinics. CAA is linked to increased risk of amyloid-related imaging abnormalities (ARIAs). The framework used by FCAAS can possibly be adapted to predict ARIAs risk.
Key findings
- The FCAAS-4 achieved a mean area under the receiver operating characteristic curve (AUC-ROC) of 0.74 (95% confidence interval: 0.71-0.77) and a Harrell generalized c-index of 0.72 (0.70-0.75).
- Pilot trial results obtained a mean AUC-ROC of 0.82 (0.71-0.85) and Harrell generalized c-index 0.79 (0.73-0.82).
- The FCAAS models demonstrate a promising performance in predicting CAA severity.
- This framework holds the potential for predicting development of amyloid-related imaging abnormalities (ARIAs), given the CAA-ARIAs link.
- HIGHLIGHTS: The severity of cerebral amyloid angiopathy (CAA) can only be determined post mortem.
Why it matters
A web tool, the Florey CAA Score, was developed to predict cerebral amyloid angiopathy severity, which can otherwise only be determined after death, and showed promising performance in the reported models. It is a risk-stratification tool and does not treat, cure or prevent Alzheimer's disease.
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yijun Pan: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Melbourne: institution h-index 1,342 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40042448) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Chu, C., Wang, Y., Ma, L., Mutimer, C. A., Ji, G., Shi, H., et al. (2025). Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14583
Vancouver
Chu C, Wang Y, Ma L, Mutimer CA, Ji G, Shi H, et al. Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14583. PMID: 40042448.
BibTeX
@article{chu2025-40042448,
author = {Chu, Chenyin and Wang, Yihan and Ma, Liwei and Mutimer, Chloe A. and Ji, Guangyan and Shi, Huiyu and Yassi, Nawaf and Masters, Colin Louis and others},
title = {{Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.14583},
pmid = {40042448},
url = {https://doi.org/10.1002/alz.14583}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.